897
Views
18
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Health-Related Quality of Life in Patients with Alpha-1 Antitrypsin Deficiency: The French Experience

, , , , , , , & show all

References

  • Stoller JK, Aboussouan LS. A review of alpha1-antitrypsin deficiency. Amer J Respir Crit Care Med 2012; 185(3):246–259.
  • Lomas DA. The selective advantage of alpha1-antitrypsin deficiency. Amer J Respir Crit Care Med 2006; 173(10):1072–1077.
  • de Serres FJ. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002; 122(5):1818–1829.
  • de Serres FJ, Blanco I, Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet 2003; 64(5):382–397.
  • de Serres FJ, Blanco I, Fernandez-Bustillo E. PI S and PI Z alpha-1 antitrypsin deficiency worldwide. A review of existing genetic epidemiological data. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace/Fondazione clinica del lavoro, IRCCS [and] Istituto di clinica tisiologica e malattie apparato respiratorio, Universita di Napoli, Secondo ateneo. Dec 2007;67(4):184–208.
  • Thabut G. [National cohort of patients with emphysema and alpha-1 antitrypsin deficiency]. Revue des Maladies Respir 2005; 22(6 Pt 1):1053–1057.
  • Thabut G, Mornex JF, Cuvelier A, et al. [Characteristics of the patients included in the French cohort of patients with emphysema caused by alpha-1 antitrypsin deficiency]. Revue des Maladies Respir 2008; 25(9):1115–1122.
  • Thabut G, Mornex JF, Pison C, et al. Performance of the BODE index in patients with alpha1-antitrypsin deficiency-related COPD. Euro Respir J 2014; 44(1):78–86.
  • Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease; 2011. Available at: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed 01/15/2015.
  • Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Amer J Respir Crit Care Med 2007; 176(6):532–555.
  • A registry of patients with severe deficiency of alpha 1-antitrypsin. Design and methods. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1994; 106(4):1223–1232.
  • Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Amer J Respir Crit Care Med 1998; 158(1):49–59.
  • Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. New Engl J Med 2011; 365(13):1184–1192.
  • Carpenter MJ, Strange C, Jones Y, et al. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Ann Behav Med 2007; 33(1):22–28.
  • Manca S, Rodriguez E, Huerta A, et al. Usefulness of the CAT, LCOPD, EQ-5D and COPDSS scales in understanding the impact of lung disease in patients with alpha-1 antitrypsin deficiency. COPD 2014; 11(5):480–488.
  • Pillai AP, Turner AM, Stockley RA. Global Initiative for Chronic Obstructive Lung Disease 2011 symptom/risk assessment in alpha1-antitrypsin deficiency. Chest 2013; 144(4):1152–1162.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.